ReviewBone marrow transplantation2016
How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Stem cell transplant and graft versus host disease: designing and implementing a steroid-induced hyperglycemia tool kit.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.Clinical hematology international · 2022Review
- How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2021Review
- Optimization of nutrition support practices early after hematopoietic cell transplantation.Bone marrow transplantation · 2021Review
- Hyponatremia in Patients with Hematologic Diseases.Journal of clinical medicine · 2020Review
- Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients.Pediatric blood & cancer · 2020Article
- Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach.Journal of blood medicine · 2020Review
- Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients.Blood advances · 2019Article
- A review of infectious complications after haploidentical hematopoietic stem cell transplantations.Infection · 2017Review
- Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation.Bone marrow transplantation · 2017Article
- Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.Oncology nursing forum · 2017Review
- Hyperglycemia as a possible risk factor for mold infections-the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Review
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.